A
Agilent Technologies, Inc. Health Care Laboratory Analytical Instruments S&P 500Russell 3000
$174.87Close
$49.5BMarket cap
$109.78 – $181.4852-week range
Nov 23, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 87 · stronger than 87% of stocks over 12 months
- Near its high 4% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 1.0%
price change
1mo
up 1.6%
price change
12-month return
up 23%
market up 11% ·
its own up 12%
F-score
5 / 9
Mixed
Altman Z
6.26
Low risk
P/E
38.0×
price / earnings
PEG
11.82
P/E / EPS growth
P/B
7.3×
price / book
Earnings yield
up 2.9%
EBIT / enterprise value
Cheaper than
36%
of the market · expensive
Revenue growth
up 7%
year on year
EPS growth
up 8%
latest quarter · -50 pts
Sales growth
up 8%
latest quarter · -2 pts
ROE
up 21%
return on equity
Free cash margin
up 17%
$1.2B FCF
D/E
0.45
long-term debt / equity
Net debt / EBITDA
0.7×
Interest cover
13.2×EBIT / interest
Piotroski tests
- profitability slipped from last year
- short-term liquidity weakened
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- no new shares issued
Repair signals
- Long-term debt down 9% ($3.3B → $3.0B)
- Revenue reaccelerating (-5% then +7%)
Trade setup
ATR%
2.9%
$5.09 a day · 2×ATR $164.68
RS
87 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
1.15
50 sessions
Implied move
11.6%
by Dec 18, 2026 · report Nov 23, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 54.3% to 52.4%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 26, 2026
Results reaction
Aug 26, 2026+1% vs market2 sessions after results
Options
$2.1M39.1% IV · activity
Financials
- Gross 52%
- Net 19%
- Free cash 17%
- Cash
- Long-term debt
| FY2020Oct 31, 2020 | FY2021Oct 31, 2021 | FY2022Oct 31, 2022 | FY2023Oct 31, 2023 | FY2024Oct 31, 2024 | FY2025Oct 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3B | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Gross margin | 53% | 54% | 54% | 51% | 54% | 52% |
| Operating income | $846.0M | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net income | $719.0M | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| Net margin | 13% | 19% | 18% | 18% | 20% | 19% |
| Earnings per share | $2.30 | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 |
| Free cash flow | $802.0M | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| Free cash margin | 15% | 21% | 15% | 22% | 21% | 17% |
| Cash | $1.4B | $1.5B | $1.1B | $1.6B | $1.3B | $1.8B |
| Long-term debt | $2.3B | $2.7B | $2.7B | $2.7B | $3.3B | $3.0B |
| Shareholders' equity | $4.9B | $5.4B | $5.3B | $5.8B | $5.9B | $6.7B |
| Shares outstanding | 306m | 302m | 295.26m | 292.12m | 285.19m | 283.05m |
Next report
Nov 23, 2026
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±11.6%
$155 – $195 by Dec 18, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±3.3%
last 4: +1.9% · +17.6% · -2.8% · +3.9%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
3.5× the usual move
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $162 – $187 ±7.1% by Nov 20, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 39.1% priced · 26.1% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- About the same
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $2.1M calls $492,332 · puts $1.6M · latest session
- 3.23× +1.01 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +281 · puts +2.35k past week
For options traders: ATM IV 39.1% (+1.0% 1w) · 1m ÷ 3m IV 1.03 · 25Δ skew 1.6 pts · Net GEX $2.3M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Sep 1, 2026 | Quarterly ↗ | Jul 31, 2026 | 32d |
| Jun 1, 2026 | Quarterly ↗ | Apr 30, 2026 | 32d |
| Mar 3, 2026 | Quarterly ↗ | Jan 31, 2026 | 31d |
| Dec 22, 2025 | Annual ↗ | Oct 31, 2025 | 52d |
| Aug 29, 2025 | Quarterly ↗ | Jul 31, 2025 | 29d |
| Jun 2, 2025 | Quarterly ↗ | Apr 30, 2025 | 33d |
| Mar 3, 2025 | Quarterly ↗ | Jan 31, 2025 | 31d |
| Dec 20, 2024 | Annual ↗ | Oct 31, 2024 | 50d |
| Aug 30, 2024 | Quarterly ↗ | Jul 31, 2024 | 30d |
| Jun 3, 2024 | Quarterly ↗ | Apr 30, 2024 | 34d |
| Mar 5, 2024 | Quarterly ↗ | Jan 31, 2024 | 34d |
| Dec 20, 2023 | Annual ↗ | Oct 31, 2023 | 50d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 8, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 26, 2026 | Results ↗ |
| Jun 25, 2026 | Material agreement · New obligation ↗ |
| May 27, 2026 | Results · Director or officer change ↗ |
| May 4, 2026 | Director or officer change · Regulation FD ↗ |
| Apr 3, 2026 | Change of control ↗ |
| Mar 20, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Mar 6, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 24, 2025 | Results ↗ |
| Oct 27, 2025 | Director or officer change ↗ |
| Aug 27, 2025 | Results ↗ |